<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384150</url>
  </required_header>
  <id_info>
    <org_study_id>114-NH-302</org_study_id>
    <nct_id>NCT00384150</nct_id>
  </id_info>
  <brief_title>Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an
      investigational drug called galiximab in combination with an approved drug called rituximab
      in subjects with relapsed or refractory, follicular NHL who demonstrated a response on Study
      114-NH-301 with a time-to-progression &gt;=6 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment challenges due to changes in standards of care resulted in premature termination. No
    safety or efficacy events factored into this action.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies</measure>
    <time_frame>Study period is approx. 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Study period is approx. 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further characterize the efficacy profile of galiximab in combination with rituximab</measure>
    <time_frame>Study period is approx. 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galiximab in combination with rituximab</intervention_name>
    <description>galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in combination
             with Rituximab compared with Rituximab in combination with Placebo) and then relapsed
             or progressed with a TTP &gt;=6 months. Relapsed disease is defined as documented disease
             progression using the International Workshop Response Criteria (IWRC).

          -  Bidimensionally measurable disease with at least 1 lesion &gt;=2.0 cm in a single
             dimension.

          -  Acceptable hematologic, hepatic, and renal function.

        Key Exclusion Criteria:

          -  Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this
             retreatment study.

          -  Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders
             within 3 weeks prior to Study Day 1.

          -  Transfusion-dependent subjects.

          -  Presence of central nervous system (CNS) lymphoma.

          -  Histologic transformation.

          -  Presence of pleural or peritoneal effusion with positive cytology for lymphoma.

          -  Another primary malignancy requiring active treatment.

          -  Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active
             uncontrolled bacterial, viral, or fungal infections; or other conditions that would
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

          -  New York Heart Association Class III or IV cardiac disease or myocardial infarction
             within 6 months prior to Study Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2006</study_first_submitted>
  <study_first_submitted_qc>October 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2006</study_first_posted>
  <disposition_first_submitted>October 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 26, 2015</disposition_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>galiximab</keyword>
  <keyword>antibody</keyword>
  <keyword>refractory</keyword>
  <keyword>follicular</keyword>
  <keyword>relapsed</keyword>
  <keyword>NHL</keyword>
  <keyword>rituximab</keyword>
  <keyword>retreatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

